ArticleClinical rheumatology2025
Cardiac involvement in established idiopathic inflammatory myopathy assessed by cardiac magnetic resonance mapping.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Arrhythmias in Autoimmune Diseases: Immune-Mediated Mechanisms and Management.Journal of cardiovascular development and disease · 2026Review
- Cardiovascular risk scores, non-invasive vascular measures and myositis damage index reveal increased cardiovascular risk in idiopathic inflammatory myopathies: a case-control study.BMC rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesTo investigate the prevalence of subclinical, myocardial involvement in patients with established idiopathic inflammatory myopathies (IIM) compared to healthy controls using T1 and T2 mapping by cardiac magnetic resonance imaging (CMRI).
methodFifty-five patients with established, stable IIM without overt cardiac involvement were consecutively enrolled in this cross-sectional study. All patients completed questionnaires, underwent clinical examination, blood tests including antibody profiling, electrocardiography, and CMRI with T1 and T2 mapping. Concurrently, CMRI was conducted on 19 healthy controls. Abnormal T1 and T2 values were defined as values exceeding the 95th percentile in the control group. Potential associations between abnormal T1 and T2 values and various cardiac- and IIM-related outcomes were assessed in exploratory analyses.
resultsAbnormal T1 values were observed in 9% of all IIM patients, displaying significantly higher T1 values compared to healthy controls (p = 0.02). T2 values were elevated in 18% of IIM patients, particularly among patients with non-inclusion body myositis (IBM) IIM compared to healthy controls (p = 0.03). No significant associations between T1 or T2 values and cardiac or disease-related measures were found in the present cohort of IIM patients.
conclusionsOur study demonstrates that subclinical cardiac involvement may be present in established, stable IIM patients, with abnormal T1 and T2 mapping observed in up to 18% of the cohort. These findings underscore the importance of ongoing cardiac monitoring, even during stable phases of the disease. However, prospective studies are needed to determine the prognostic value of T1 and T2 mapping in this disease entity. Key Points • T1 and T2 mapping on cardiac MRI identify subclinical myocardial involvement in patients with IIM. • Subclinical myocardial involvement is present in up to 18% of patients with established, stable IIM. • Cardiac T1 and T2 abnormalities are rare in patients with IBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.